Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05577988
Other study ID # APHP211027
Secondary ID 20-0570 PHRC
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date June 2024
Est. completion date January 2026

Study information

Verified date April 2024
Source Assistance Publique - Hôpitaux de Paris
Contact Michel ZEITOUNI, MD,PhD
Phone 33142165535
Email michel.zeitouni@aphp.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients who suffered from acute coronary syndrome (ACS) are usually treated with a long-term dual antiplatelet therapy (DAPT) to reduce stent thrombosis and recurrent ischemic event. Nonetheless, recent important data have demonstrated the efficacy of a short term DAPT and an early single antiplatelet therapy in high bleeding and ischemic risk patients. The bleeding risk is associated with a significant mortality. This risk is especially high in patients treated with potent P2Y12 inhibitors like ticagrelor or prasugrel after an ACS. As a result of the abounding data regarding the safety of an early single antiplatelet therapy with high potency antiplatelet therapy (ticagrelor or prasugrel), it is likely that such strategy will soon be implemented in the guidelines. The benefits of these high-potency P2Y12 inhibitors over clopidogrel mostly occur in patients with genetic polymorphisms of CYP2Y12 associated with a loss of function in clopidogrel metabolism. Furthermore, the anti-ischemic benefit of potent P2Y12 inhibitors over clopidogrel occurs early, while excess bleeding events often arise during chronic treatment. Our hypothesis is that a systematic and rapid genetic screening of CYP2C90 *2 or *17 polymorphism to guide an early single therapy with low potency antiplatelet (aspirin or clopidogrel) could lead to less bleeding events with a consistent efficacy towards cardiac events compared with high potency antiplatelet therapies (prasugrel or ticagrelor) in high bleeding risk patients treated for ACS.


Description:

Multicenter, randomized, open label trial using the PROBE study design. Randomization 1 to 3 months (preferably 1, considering the HBR) after ACS into 2 parallel arms. Stratification: according to revascularization status (PCI or no PCI), genotype (loss of function, fast metabolization, none) and center. Control arm: stop aspirin for a single antiplatelet therapy with a high-potency antiplatelet (ticagrelor or prasugrel). Intervention arm: single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 2468
Est. completion date January 2026
Est. primary completion date December 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Being 18-year-old or older - Admission for type 1 acute myocardial infarction (STEMI or NSTEMI) - Bedside genetic testing for clopidogrel resistance that can be performed during hospital stay for ACS (oral swab kit with result within 1 hour) - Treated with aspirin and ticagrelor, or aspirin and prasugrel at the screening phase and at the randomization visit. - High bleeding risk as defined by the Consensus Document From the Academic Research Consortium for High Bleeding Risk (at least one criterion) : - Age =75 years old. - Baseline haemoglobin <11 g/dl (or anaemia requiring transfusion during the 4 weeks prior to randomization). - Chronic Kidney Disease with estimated glomerular filtration rate = 30 ml/min. - Thrombocytopenia with platelet count < 100 x 109 / L - Chronic bleeding diatheses: inherited or acquired conditions known to be associated with increased bleeding risk such as platelet dysfunction, von Willebrand disease (prevalence of 1%-2% in the general population), inherited or acquired clotting factor deficiencies (including factors VII, VIII [hemophilia A], IX [hemophilia B], and XI), or acquired antibodies to clotting factors, among others. - Cirrhosis with portal hypertension. - PCI after major traumatism or surgery. - Any documented stroke in the last 12 months. - Hospital admission for bleeding or transfusion within last 6 months. - Nonskin cancer diagnosed or treated =3 years. - Planned daily nonsteroidal anti-inflammatory drugs (other than aspirin) or steroids for =30 days after PCI. - patient affiliated to a social security system - signed informed consent form - For women of childbearing potential, an effective contraception method must be used up to the visit V3 Exclusion Criteria: - Enrolled in another clinical trial except non interventional studies - Any prior documented intracerebral bleed - Contra-indication, known allergy or expected interactions with clopidogrel. Baseline treatment (at screening) should not include an antiplatelet therapy for which a contra-indication, known allergy or expected interactions is known (example history of stroke and use of prasugrel, or concomitant use of ticagrelor and ritonavir) - Patients on concomitant treatment with an anticoagulant agent (Vitamin-K antagonists or novel oral anticoagulants such as rivaroxaban, dabigatran or apixaban) - Planned surgery within 12 coming months - Patient under guardianship or curatorship - Pregnancy or breastfeeding - Inability to sign the informed consent form

Study Design


Intervention

Other:
single-antiplatelet with a low-potency antiplatelet (aspirin or clopidogrel) guided by genetic testing.
Individuals without genetic loss of function to metabolize clopidogrel: stop DAPT and switch to a single antiplatelet therapy by clopidogrel. Individuals with genetic loss of function to metabolize clopidogrel (*2/*3, 1/*3, *2/*2, *1/*2): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin. Individuals with fast metabolization of clopidogrel (*1/*17 or *17/*17): stop potent P2Y12 inhibitor and treat with a single antiplatelet therapy by aspirin.

Locations

Country Name City State
France Hopital Pitié Salpetrière Paris IDF

Sponsors (2)

Lead Sponsor Collaborator
Assistance Publique - Hôpitaux de Paris Fonds de Dotation ACTION

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of combinated major and minor bleeding events (BARC 2 to 5 BARC) the occurrence of major or minor bleeding events between randomization to one of the de-escalation strategies and 1 year after index ACS defined according to the Bleeding Academic Research Consortium (BARC) classification as type 2 to 5 From randomization (1-3months after inclusion) to 1year after inclusion
Secondary Rate of major adverse cardiovascular events major adverse cardiovascular events defined as follow and in the following hierarchical order:
Death or myocardial infarction or stroke or stent thrombosis (key secondary)
Death or Myocardial infarction
From randomization to de-escalation (1-3months) to 1year
Secondary Rate of major bleeding events the occurrence of major bleeding events between randomization to one of the de-escalation strategies and 1 year after index ACS defined according to the Bleeding Academic Research Consortium (BARC) classification randomization to de-escalation (1-3months) to 1year
Secondary Rate of minor bleeding events the occurrence of minor bleeding events between randomization to one of the de-escalation strategies and 1 year after index ACS defined according to the Bleeding Academic Research Consortium (BARC) classification randomization to de-escalation (1-3months) to 1year
See also
  Status Clinical Trial Phase
Recruiting NCT06013813 - Conventional vs. Distal Radial Access Outcomes in STEMI Patients Treated by PCI N/A
Completed NCT04507529 - Peer-mentor Support for Older Vulnerable Myocardial Infarction Patients N/A
Recruiting NCT06066970 - Cardiac Biomarkers for the Quantification of Myocardial Damage After Cardiac Surgery
Recruiting NCT03620266 - Effects of Bilberry and Oat Intake After Type 2 Diabetes and/or MI N/A
Completed NCT04097912 - Study to Gather Information to What Extent Patients Follow the Treatment Regimen of Low-dose Aspirin for Primary and Secondary Prevention of Diseases of the Heart and Blood Vessels
Completed NCT04153006 - Comparison of Fingerstick Versus Venous Sample for Troponin I.
Completed NCT03668587 - Feasibility and Security of a Rapid Rule-out and rule-in Troponin Protocol in the Management of NSTEMI in an Emergency Departement
Recruiting NCT01218776 - International Survey of Acute Coronary Syndromes in Transitional Countries
Completed NCT03076801 - Does Choral Singing Help imprOve Stress in Patients With Ischemic HeaRt Disease? N/A
Recruiting NCT05371470 - Voice Analysis Technology to Detect and Manage Depression and Anxiety in Cardiac Rehabilitation N/A
Recruiting NCT04562272 - Attenuation of Post-infarct LV Remodeling by Mechanical Unloading Using Impella-CP N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Active, not recruiting NCT04475380 - Complex All-comers and Patients With Diabetes or Prediabetes, Treated With Xience Sierra Everolimus-eluting Stents
Not yet recruiting NCT06007950 - Time-restricted Eating Study (TRES): Impacts on Anthropometric, Cardiometabolic and Cardiovascular Health N/A
Withdrawn NCT05327855 - Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI) Phase 2
Recruiting NCT02876952 - High Intensity Aerobic Interval Training With Mediterranean Diet Recommendations in Post-Myocardial Infarct Patients N/A
Completed NCT02711631 - Feasibility and Effectiveness of Remote Virtual Reality-Based Cardiac Rehabilitation N/A
Completed NCT02917213 - Imaging Silent Brain Infarct And Thrombosis in Acute Myocardial Infarction
Completed NCT02305602 - A Study of VentriGel in Post-MI Patients Phase 1
Completed NCT02382731 - Interventions to Support Long-Term Adherence aNd Decrease Cardiovascular Events Post-Myocardial Infarction N/A